Idorsia’s Tryvio: First FDA-Approved Endothelin Receptor Antagonist for Hypertension
Idorsia has released an on-demand investor briefing positioning Tryvio (aprocitentan) as a foundational add-on for difficult-to-control hypertension, with a...
Idorsia has released an on-demand investor briefing positioning Tryvio (aprocitentan) as a foundational add-on for difficult-to-control hypertension, with a...
Rhythm Pharmaceuticals will put its story in front of Wall Street next month, with its chair, president, and CEO...
FDA has approved Pfizer and BioNTech’s LP.8.1-adapted monovalent Comirnaty for adults 65 and older and for individuals 5 to...
Moonlake Immunotherapeutics reported 16-week results from its two identically designed Phase 3 VELA trials of sonelokimab in moderate-to-severe hidradenitis...
China’s National Medical Products Administration has approved once-every-four-weeks intravenous maintenance dosing for Leqembi (lecanemab), following 18 months of 10...
MoonLake Immunotherapeutics reported week 16 readouts from its two pivotal Phase 3 trials in hidradenitis suppurativa. In VELA-1, sonelokimab...
Profusa has entered a commercial and clinical collaboration with Prof. Dr. Marianne Brodmann at the Medical University of Graz,...
Onconetix has closed a $12.9 million private placement comprising Series D convertible preferred stock and warrants, using the raise...
FDA has expanded Evkeeza (evinacumab-dgnb) to children aged 1 to under 5 with homozygous familial hypercholesterolemia, completing a stepwise...
PrestoDoctor, a telemedicine platform focused on medical cannabis evaluations and a subsidiary of Dogecoin Cash, has expanded into Connecticut,...